ALArturo Llobell-Uriel

Arturo Llobell-Uriel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Arturo Llobell-Uriel has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Adrian Martín-Gutiérrez

    Department of Rheumatology, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain

    1 shared publication
  • Albert Pérez-Isidro

    Department of Immunology, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Villarroel 170-Escala 4, Planta 0, 08036 Barcelona, Spain

    1 shared publication
  • Almudena García-Castaño

    Department of Oncology, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain

    1 shared publication
  • Antoni Berenguer-Llergo

    Department of Rheumatology, Parc Taulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona Medicine Department, Sabadell, Spain

    1 shared publication
  • Antonio Gómez-Centeno

    Department of Rheumatology, Parc Taulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona Medicine Department, Sabadell, Spain

    1 shared publication
  • Carmen Secada-Gómez

    Department of Rheumatology, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain

    1 shared publication

Latest Publications

  • Open Access

    Rheumatic immune-related adverse effects of immune checkpoint treatment: a retrospective multicentre study

    by Arturo Llobell-Uriel, Íñigo González-Mazón, Jordi Gratacós, Soledad Retamozo, Carmen Secada-Gómez, Adrian Martín-Gutiérrez, Almudena García-Castaño, Luis Fernández-Morales, Enrique Gallardo-Diaz, Antoni Berenguer-Llergo, et al.

    To describe the frequency, clinical spectrum, and management of rheumatic immune-related adverse events (R-irAEs) in patients receiving immune checkpoint inhibitors (ICIs) at two oncology centers in Spain. This was a retrospective, observational study involving 734 patients treated with ICIs between January 2016 and December 2022 in two Spanish hospitals. Electronic medical records were systematically reviewed to identify R-irAEs, with diagnoses confirmed by rheumatologists. The data collected included demographics, cancer type, ICI regimen, time to R-irAE onset, clinical features, management, and outcomes. Among the 734 patients, 227 (30.9%) developed any irAEs, with 54 (7.35%) presenting R-irAEs, accounting for 23.8% of all irAEs. The most common cancers were lung cancer and melanoma. Most R-irAEs occurred within six months of ICI initiation. The most frequent manifestations were polymyalgia rheumatica (n = 12) and various forms of arthritis/arthralgia (n = 26). Myositis is a particularly severe manifestation that presents at the first or second cycle of treatment. Corticosteroids are the primary treatment, with some patients requiring immunosuppressants, biologics, or intravenous immunoglobulins. Clinical improvement was observed in 88% of the treated patients, although 18 patients required ICI discontinuation due to toxicity. The increasing use of ICIs in cancer treatment is limited by development of irAEs (30.9%) and R-irAEs (7.35%) accounting for 23.8% of irAEs. Prompt recognition and multidisciplinary management, including rheumatology input, are essential to optimize patient outcomes and balance the continuation of cancer treatment. Greater awareness and standardized guidelines are needed to improve the diagnosis and care of these adverse events.


  • Open Access

    Anti-dsDNA B-Cell ELISpot as a Monitoring and Flare Prediction Tool in SLE Patients

    by Albert Pérez-Isidro, Marc Xipell, Arturo Llobell, Noemí De Moner, Gema M. Lledó, Ricard Cervera, Sergio Prieto-González, Luis F. Quintana, Gerard Espinosa, Mila García-Ormaechea, et al.

    Anti-dsDNA autoantibodies quantification and complement levels are widely used to monitor disease activity in systemic lupus erythematosus (SLE). However, better biomarkers are still needed. We hypothesised whether the dsDNA antibody-secreting B-cells could be a complementary biomarker in disease activity and prognosis of SLE patients. Fifty-two SLE patients were enrolled and followed for up to 12 months. Additionally, 39 controls were included. An activity cut-off (comparing active and non-active patients according to clinical SLEDAI-2K) was established for SLE-ELISpot, chemiluminescence and Crithidia luciliae indirect immunofluorescence tests (≥11.24, ≥374.1 and ≥1, respectively). Assays performances together with complement status were compared regarding major organ involvement at the inclusion and flare-up risk prediction after follow-up. SLE-ELISpot showed the best performance in identifying active patients. High SLE-ELISpot results were associated with haematological involvement and, after follow-up, with an increased hazard ratio for disease flare-up (3.4) and especially renal flare (6.5). Additionally, the combination of hypocomplementemia and high SLE-ELISpot results increased those risks up to 5.2 and 32.9, respectively. SLE-ELISpot offers complementary information to anti-dsDNA autoantibodies to evaluate the risk of a flare-up in the following year. In some cases, adding SLE-ELISpot to the current follow-up protocol for SLE patients can improve clinicians’ personalised care decisions.